PROGNYX

Home/The Watchtower/Summit files HARMONi-2 OS-positive update for ivonescimab

Editorial illustration for the Prognyx briefing on ivonescimab — PD-1 × VEGF bispecific antibody

Briefing · From the Watchtower

Summit files HARMONi-2 OS-positive update for ivonescimab

Summit’s 3 September 2026 8-K says Akeso reported statistically significant OS improvement for ivonescimab monotherapy versus pembrolizumab monotherapy in China’s HARMONi-2 Phase III trial in PD-L1-positive advanced NSCLC. [1]

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief — Summit’s 3 September 2026 8-K says Akeso reported statistically significant overall-survival improvement for ivonescimab monotherapy versus pembrolizumab monotherapy in the randomized, double-blind China Phase III HARMONi-2 trial in PD-L1-positive locally advanced or metastatic NSCLC, where OS was a secondary endpoint. [1] HARMONi-2 had already met its PFS primary endpoint by independent radiologic review committee with HR 0.51, 95% CI 0.38-0.69 and p<0.0001, and Akeso received China NMPA marketing authorization for ivonescimab in April 2025 based on HARMONi-2 results. [2] Ivonescimab remains investigational and unapproved in Summit’s license territories, including the United States and Europe, while Summit’s separate HARMONi BLA has a PDUFA goal date of 14 November 2026 in EGFR-mutated NSCLC after third-generation EGFR TKI treatment. [2]

Summit’s 3 September 2026 filing states that Akeso announced statistically significant overall-survival improvement for ivonescimab monotherapy versus pembrolizumab monotherapy in PD-L1-positive locally advanced or metastatic NSCLC. [1]

The questionThe answer
What changed?OS was statistically significant versus pembrolizumab. [1]
Trial design?Randomized, double-blind China Phase III. [1]
Prior efficacy anchor?PFS HR 0.51, p<0.0001. [2]
Approved where?China; investigational in U.S. and Europe. [2]
Active high-PD-L1 study?NCT06767514 is recruiting, with OS and PFS. [5]
U.S. regulatory date?HARMONi PDUFA goal: 14 November 2026. [2]
Still missing?Exact OS HR, medians, safety and subgroups. [1]

What happened

Summit filed an 8-K on 3 September 2026 stating that partner Akeso announced positive overall-survival results from HARMONi-2, a randomized, double-blind Phase III study of ivonescimab monotherapy versus pembrolizumab monotherapy in PD-L1-positive locally advanced or metastatic NSCLC. [1]

OS was a secondary endpoint in a preplanned analysis, and Akeso reported statistically significant improvement for ivonescimab monotherapy versus pembrolizumab monotherapy. [1]

The filing identifies HARMONi-2 as a single-region, multi-center Phase III study conducted in China, sponsored by Akeso, with all relevant data generated, managed and analyzed exclusively by Akeso. [1]

The prior anchor is now more consequential: Summit’s attached release says HARMONi-2 met its primary endpoint of PFS by independent radiologic review committee versus pembrolizumab, with HR 0.51, 95% CI 0.38-0.69 and p<0.0001. [2]

Akeso received China NMPA marketing authorization for ivonescimab in April 2025 based on HARMONi-2 results, while Summit says ivonescimab remains investigational and unapproved in Summit’s license territories, including the United States and Europe. [2]

Why it matters

Ivonescimab, known as SMT112 in Summit license territories and AK112 outside them, is described by Summit as a bispecific antibody combining PD-1 blockade and VEGF blockade in one molecule. [2]

Prognyx read: the competitive point is not that HARMONi-2 alone settles Western regulatory adoption, but that the same trial now gives Akeso and Summit a clinical story with both PFS and OS directionally aligned against pembrolizumab monotherapy. [1][2]

A pembrolizumab-controlled, double-blind Phase III trial in PD-L1-positive advanced NSCLC sits directly on the PD-1 backbone question, because the control arm was pembrolizumab monotherapy and the experimental arm was ivonescimab monotherapy. [1]

The limitation is equally material: the public dossier gives no exact OS hazard ratio, confidence interval, p value, median OS, safety update or subgroup OS results for HARMONi-2. [1]

For a biotech operator, the near-term issue is whether the OS magnitude and safety profile, once presented, support a global risk-benefit argument outside China. [1][2]

Summit says more than 4,000 patients have been treated with ivonescimab in clinical studies globally and more than 70,000 patients when including commercial treatment in China, as noted by Akeso. [2]

That exposure base helps the strategic narrative, but it does not replace the missing HARMONi-2 OS effect size, subgroup behavior or regulator-facing dataset details. [1][2]

Who is exposed — by name

Direct exposure sits with companies whose cited registry entries test ivonescimab or AK112-containing regimens, because HARMONi-2 is the ivonescimab monotherapy trial now reported OS-positive by Summit. [1][18][20]

Multitude Therapeutics is direct-by-combination: NCT07590531 is recruiting patients with lung cancer to test AMT-116 in combination with AK112. [18]

MediLink Therapeutics is direct to ivonescimab combination biology but not shown in the dossier to be NSCLC-specific, because NCT07208773 is recruiting patients with advanced solid tumors to test YL201 with ivonescimab. [20]

Lung-program exposure sits with BioNTech, because NCT06892548 is recruiting patients with advanced lung cancer to study BNT324 with BNT327, and NCT06841055 is recruiting patients with NSCLC to study pumitamig with docetaxel. [15][16]

BioNTech also has comparator/sequencing exposure through NCT05142189, a recruiting Phase 1 study in advanced NSCLC that tests BNT116 alone and in combinations including cemiplimab, docetaxel and carboplatin. [14]

DualityBio is solid-tumor and lung-screen adjacent through NCT06953089, a recruiting Phase 2 study in advanced or metastatic solid tumors testing DB-1311/BNT324 with BNT327 and DB-1305/BNT325. [19]

Calico is mechanism-adjacent through NCT04777994, a recruiting Phase 1 study in locally advanced or metastatic tumors that includes ABBV-CLS-484 alongside VEGFR TKI and PD-1 inhibitor interventions. [21]

Neonc Technologies is comparator-adjacent through NCT06047379, a recruiting Phase 1/2 study that includes pembrolizumab and nivolumab among interventions in patients with astrocytoma, glioblastoma or brain metastasis; the dossier does not support an NSCLC-line match for this listing. [17]

Huahui Health is category-adjacent rather than directly exposed, because NCT07623369 is a recruiting first-in-human study of HH160 in advanced or metastatic solid tumors without the dossier specifying a PD-1/VEGF mechanism or NSCLC-line match. [22]

Prognyx read: greater exposure sits with programs that either use ivonescimab/AK112 or test lung-cancer regimens that could be benchmarked against a pembrolizumab-controlled HARMONi-2 signal. [1][2][15][18][20]

What to watch next

The next data release is the upcoming medical-conference presentation of HARMONi-2 OS results, because Summit says the analysis is scheduled for presentation but the dossier does not provide the conference name, date, OS hazard ratio, median OS, safety or subgroups. [1]

NCT05899608 is recruiting in first-line metastatic NSCLC and tests ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy, with OS and investigator-assessed PFS as primary outcomes. [4]

NCT06767514 is recruiting in first-line metastatic NSCLC with high PD-L1 and evaluates OS and PFS; the dossier does not provide enough comparator or location detail to characterize it as a global monotherapy bridge. [5]

Summit’s separate HARMONi program in EGFR-mutated locally advanced or metastatic non-squamous NSCLC after third-generation EGFR TKI treatment has a BLA accepted for filing in January 2026 and a PDUFA goal date of 14 November 2026. [2]

That 14 November 2026 date is the explicit U.S. regulatory calendar item in the dossier; it concerns ivonescimab plus chemotherapy versus placebo plus chemotherapy in EGFR-mutated NSCLC after third-generation EGFR TKI treatment, not HARMONi-2. [2]

The Lancet Oncology article dated 1 September 2026 concerned ivonescimab plus chemotherapy versus placebo plus chemotherapy in advanced EGFR-mutated NSCLC after progression on EGFR tyrosine kinase inhibitor therapy in the HARMONi multicenter randomized double-blind Phase III trial. [8]

Outside NSCLC, Summit stated in August 2026 that Akeso’s China Phase III HARMONi-GI1 in first-line advanced biliary tract cancer achieved statistically significant and clinically meaningful OS superiority for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy, and also met PFS and ORR key secondary endpoints. [6]

Summit also stated on 5 August 2026 that it initiated global Phase II/III HARMONi-GU1 in first-line locally advanced or metastatic urothelial carcinoma, comparing ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin, with planned Phase III primary endpoints of PFS and OS. [7]

The three decision implications are China monotherapy OS transferability in PD-L1-positive NSCLC, the 14 November 2026 U.S. EGFR-mutated NSCLC BLA decision date, and non-NSCLC expansion risk in biliary tract and urothelial carcinoma. [1][2][6][7]

What Prognyx could not verify

Prognyx could not confirm Akeso’s original company release for the 2026 HARMONi-2 OS analysis, the HARMONi-2 registry record or NCT identifier, posted registry results, exact OS hazard ratio, median OS, OS p value, safety update, subgroup OS results, or the conference date from the public sources included in the dossier. [1][2]

Prognyx could not independently confirm FDA or label status for ivonescimab from FDA records in the dossier; the available source is Summit’s statement that ivonescimab is approved and commercially available in China for NSCLC indications and remains investigational in Summit territories including the United States and Europe. [2]

The now-what

Option one is to treat HARMONi-2 as a gating signal for PD-1/VEGF threat modeling, but not as a finished global benchmark until OS magnitude, safety and subgroup data are public. [1][2]

Option two is to stress-test every NSCLC asset against two separate comparators: pembrolizumab-based standard arms for direct first-line competition and ivonescimab-containing regimens for future sequencing risk. [1][4][5]

Option three is to time BD and clinical-positioning work around the 14 November 2026 PDUFA goal date for the separate HARMONi BLA and the pending HARMONi-2 medical-conference disclosure, because one event is a dated U.S. regulatory decision point and the other is the missing efficacy-detail unlock. [1][2]

Verdict: Prognyx rates this as a high-priority diligence signal for PD-1/VEGF and pembrolizumab-adjacent NSCLC programs, pending OS magnitude, safety and subgroup disclosure. [1][2][4][5]

Questions this briefing answers

Did HARMONi-2 show an overall-survival benefit?

Summit’s 3 September 2026 8-K says Akeso reported statistically significant OS improvement for ivonescimab monotherapy versus pembrolizumab monotherapy in a preplanned secondary-endpoint analysis of HARMONi-2. [1] The dossier does not provide the OS hazard ratio, median OS, OS p value, safety update or subgroup results. [1]

Is ivonescimab approved in the United States or Europe?

Summit says ivonescimab is approved and commercially available in China for NSCLC indications, based on China NMPA marketing authorization in April 2025. [2] Summit also says ivonescimab remains investigational and unapproved in its license territories, including the United States and Europe. [2]

Which active NSCLC trials matter most for global read-through?

NCT05899608 is recruiting in first-line metastatic NSCLC and tests ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy with OS and investigator-assessed PFS as primary outcomes. [4] NCT06767514 is recruiting in first-line metastatic high-PD-L1 NSCLC and evaluates OS and PFS, but the dossier does not provide its comparator or location detail. [5]

What is the dated U.S. regulatory event in the dossier?

Summit says the separate HARMONi BLA in EGFR-mutated locally advanced or metastatic non-squamous NSCLC after third-generation EGFR TKI treatment was accepted for filing in January 2026 and has a PDUFA goal date of 14 November 2026. [2] That regulatory clock is not the HARMONi-2 monotherapy trial. [1][2]

Sources — every claim traces to the primary record

  1. Summit Therapeutics SEC 8-K, 3 September 2026
  2. Summit Therapeutics SEC 8-K exhibit / HARMONi-2 press release
  3. ClinicalTrials.gov NCT05899608
  4. ClinicalTrials.gov NCT05899608
  5. ClinicalTrials.gov NCT06767514
  6. Summit Therapeutics SEC 8-K exhibit / HARMONi-GI1 press release
  7. Summit Therapeutics SEC 8-K exhibit / HARMONi-GU1 announcement
  8. Lancet Oncology DOI 10.1016/S1470-2045(26)00282-2
  9. ClinicalTrials.gov NCT05142189
  10. ClinicalTrials.gov NCT06892548
  11. ClinicalTrials.gov NCT06841055
  12. ClinicalTrials.gov NCT06047379
  13. ClinicalTrials.gov NCT07590531
  14. ClinicalTrials.gov NCT06953089
  15. ClinicalTrials.gov NCT07208773
  16. ClinicalTrials.gov NCT04777994
  17. ClinicalTrials.gov NCT07623369

How this briefing was produced — Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets — sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.